Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents, restricted cash, and fixed-term deposits amounted to $211 million, a decrease of $53 million from $264 million as of December 31, 2024, primarily due to cash payments and operational expenses [20][21] - The company reported a consolidated net loss attributable to shareholders for the twelve months ended December 31, 2025, with specific figures available in the press release [21] Business Line Data and Key Metrics Changes - The allogeneic CAR-T candidate lasme-cel achieved a 100% overall response rate in the target phase 2 population, converting all patients to transplant-eligible candidates [6][13] - The dual CAR-T candidate eti-cel demonstrated an 88% overall response rate and a 63% complete response rate in heavily pre-treated patients [9][16] Market Data and Key Metrics Changes - Cellectis is advancing its pivotal phase 2 trial for lasme-cel, with site openings in North America and Europe expected to continue into 2026 [8] - The company is also collaborating with partners like Servier and Allogene, with key milestones anticipated in 2026 [19] Company Strategy and Development Direction - Cellectis aims to transform into a late-stage development organization, focusing on delivering clinical results for patients with no therapeutic solutions [4][11] - The company is committed to internalizing its manufacturing capabilities, which has shown improved efficacy compared to external manufacturing [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position to fund operations into the second half of 2027, allowing for continued development of lasme-cel and eti-cel [18] - The management highlighted the importance of their allogeneic CAR-T products in addressing unmet medical needs in oncology, particularly for patients with aggressive diseases [4][6] Other Important Information - The anticipated BLA submission for lasme-cel is planned for the second half of 2028, while eti-cel is expected to progress to pivotal phase 2 in 2027 with a BLA submission in H2 2029 [16] - The company is actively engaging in partnerships to enhance its gene editing platform and expand its product offerings [10][11] Q&A Session Summary Question: Update on lasme-cel and BALLI-01 enrollment - Management confirmed that recruitment is on track and expects to complete data analysis by the end of the year for the first 40 patients [24] Question: Expectations for dose optimization in the pivotal study - Management indicated that they anticipate being able to differentiate between the two dose levels of alemtuzumab based on efficacy and safety [25] Question: Details on Servier arbitration and its impact - The arbitration ruling allowed Cellectis to regain rights to UCART19, while remaining eligible for milestones related to cema-cel [30] Question: Importance of alemtuzumab in lymphodepletion - Management emphasized that alemtuzumab is critical for optimizing lymphodepletion and achieving better patient outcomes [33] Question: Update on esiCell and patient follow-up - Management provided a top-line update indicating strong complete remission rates and plans for further data sharing by the end of the year [37] Question: Application of lymphodepletion in outpatient settings - Management noted that regulatory requirements currently necessitate inpatient delivery, but there is potential for future outpatient use [58] Question: AstraZeneca partnership updates - Management expressed satisfaction with the collaboration but indicated that updates would be limited at AstraZeneca's request due to competitive considerations [60]

Group 1 - The allogeneic CAR-T sector faced significant setbacks after the FDA imposed a clinical hold on Allogene's ALLO-501A in 2021, leading to a drastic drop in stock price from $25/share to $13/share in a single day [1] - The biotech sector is perceived to be on the verge of a transformative era, with expectations for revolutionary breakthroughs in treating diseases such as cancer, Alzheimer's, and various autoimmune disorders [1] - Technological advancements are anticipated to accelerate, with innovations like fusion energy, solid-state batteries, and nanomaterials expected to become prevalent in the near future [1] Group 2 - The author has a beneficial long position in the shares of CRBU, indicating a personal investment interest in the company [2] - The article reflects the author's personal opinions and is not influenced by any compensation from companies mentioned [2]

Summary of CRISPR Therapeutics Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: Virtual Oncology Leadership Summit - **Date**: February 18, 2026 Key Points Industry Focus - CRISPR Therapeutics is engaged in multiple disease areas, with a strong focus on oncology, cardiovascular diseases, autoimmune diseases, and Type 1 diabetes [3][4] Oncology Programs - **ZugoCell (formerly CTX112)**: A next-generation allogeneic CAR-T therapy targeting CD19, designed to improve potency and safety compared to earlier generations [4][5] - **Allogeneic CAR-T**: Made from healthy donor-derived cells, with advanced edits to enhance efficacy and safety, aiming for autologous-like performance [5][6] Key Edits in ZugoCell - **Beta-2M Knockout**: Prevents immune system from recognizing allogeneic cells as foreign, enhancing persistence [8][9] - **RGNASE1 Knockout**: Retains a naive T cell phenotype, allowing for better expansion and reduced exhaustion [10][11] - **TGF-beta Receptor 2 Knockout**: Prevents exhaustion of CAR-T cells, enhancing potency [10][11] Clinical Strategy - **Autoimmune Diseases**: Rapidly enrolling patients for indications like lupus, myositis, and scleroderma, with plans to expand further [17][18] - **Oncology**: Aiming for high complete response (CR) rates and durability, with initial CR rates for ZugoCell reaching nearly 70% [20][21] Regulatory Pathway - Parallel development in oncology and autoimmune indications, with discussions with regulators expected to guide future trials [27][28] Pricing Strategy - Targeting a price point of around $200K for allogeneic CAR-T therapies, significantly lower than current autologous therapies priced at $350K-$400K [52][53] In Vivo CAR-T Development - Developing both transient and permanent CAR-T therapies using LNP-mediated delivery, with a focus on safety and efficacy [54][55] - Permanent CARs could potentially eliminate tumors with a single injection, offering a significant advancement in oncology [56][57] Market Opportunities - Significant potential in both U.S. and international markets, particularly in regions where autologous therapies are not feasible due to cost and availability [48][49] Future Directions - Continued focus on data collection and analysis in both oncology and autoimmune spaces, with a strong emphasis on achieving long-term remissions and safety [31][32][39] Conclusion - CRISPR Therapeutics is positioned to make significant advancements in both oncology and autoimmune therapies through innovative CAR-T technologies, with a clear strategy for regulatory approval and market entry.

Core Insights - Cellectis S.A. (CLLS) is a biotech company focused on developing allogeneic CAR-T therapies using its proprietary Transcription Activator-Like Effector Nucleases (TALEN) technology and PulseAgile electroporation [1] Company Overview - Cellectis targets high-unmet medical needs and heavily pretreated patients suffering from B-cell malignancies [1]